Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03846310 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT03846310 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 77 participants.
The verdict
NCT03846310, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Zimberelimab
- DRUG Etrumadenant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2024-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03846310
The ClinicalTrials.gov registry entry for NCT03846310 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03846310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03846310 about?
NCT03846310 is a clinical study titled "A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer". This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pe...
What is the current status of trial NCT03846310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2019-04-01. Estimated completion is 2024-11-18.
What interventions are being tested in trial NCT03846310?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Zimberelimab (DRUG), Etrumadenant (DRUG).
Who is sponsoring clinical trial NCT03846310?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.